FrontView REIT, Inc. FVR 深 沪
等待开盘 12-19 09:30:00 美东时间
15.62
+0.210
+1.36%
华盛通- 最 高15.7299
- 今 开15.53
- 成交量 4.05万股
- 最 低 15.415
- 昨 收 15.41
- 总市值 3.38亿
- 52周最高 17.755
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 10.18
- 委 比 -94.17%
- 总股本 2165.37万
- 历史最高 18.90
- 量 比 0.86
- 振 幅 2.04%
- 历史最低 10.18
- 每 手 1
- 风险率 2.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
JP Morgan Maintains Neutral on FrontView REIT, Raises Price Target to $17
JP Morgan analyst Anthony Paolone maintains FrontView REIT (NYSE:FVR) with a Neutral and raises the price target from $15 to $17.
12-08 23:55
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Wells Fargo Maintains Overweight on FrontView REIT, Raises Price Target to $18
Wells Fargo analyst John Kilichowski maintains FrontView REIT (NYSE:FVR) with a Overweight and raises the price target from $17 to $18.
11-26 01:17
FrontView REIT Raises FY2025 FFO Guidance from $1.22-$1.24 to $1.23-$1.25 vs $1.05 Est
2025 GUIDANCE UPDATEThe following table summarizes the Company's guidance and key underlying assumptions for the year ended December 31, 2025. PriorCurrentAFFO per share$1.22 to $1.24$1.23 to $1.25Investment
11-13 05:18
FrontView REIT Q3 AFFO $0.32 Beats $0.25 Estimate, FFO $0.25, Sales $16.803M Miss $17.442M Estimate
FrontView REIT (NYSE:FVR) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.25 by 28 percent. This is a 45.45 percent increase over earnings of $0.22 per share from the same
11-13 05:16
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Earnings Preview For FrontView REIT
FrontView REIT (NYSE:FVR) is set to give its latest quarterly earnings report o...
11-12 02:03
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
